PF-07817883 for COVID-19
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if PF-07817883 (Ibuzatrelvir) is safe and how it moves through the body. Researchers are studying PF-07817883 as a potential treatment for COVID-19. Participants will take the drug orally, possibly up to twice a day. The trial will also examine how diet might affect the drug and whether it interacts with midazolam. The study seeks healthy individuals without major health issues who identify as Japanese or Chinese based on their family's background. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
Yes, you will need to stop taking any prescription or nonprescription drugs, as well as dietary and herbal supplements, at least 28 days before the first dose of the study medicine.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that Ibuzatrelvir (PF-07817883) is generally safe for people. Studies have found it causes no more side effects than a sugar pill. Early results suggest few safety concerns, reassuring those considering joining a trial. Notably, this treatment has been tested on healthy individuals, and no major safety issues have been reported.12345
Why are researchers excited about this trial's treatments?
Researchers are excited about PF-07817883 because it appears to have a unique mechanism of action distinct from standard treatments. While most current options might target specific symptoms or pathways, PF-07817883 is being studied for its safety and how it behaves in the body in different dosing regimens, including various formulations and intake conditions (fed versus fasted). This versatility in administration could lead to more tailored treatment plans for different populations, like Japanese and Chinese individuals, potentially improving effectiveness and reducing side effects. Additionally, the trial includes comparisons with known medications like midazolam and moxifloxacin, highlighting its potential to be integrated into existing therapeutic frameworks. Researchers hope these features will make PF-07817883 a promising new option for addressing unmet needs in treatment.
What evidence suggests that PF-07817883 might be an effective treatment for COVID-19?
Research has shown that PF-07817883, also known as ibuzatrelvir, is a pill developed to treat COVID-19. It blocks a specific enzyme the virus needs to multiply. Lab tests have demonstrated that ibuzatrelvir is very effective against the virus and poses a low risk of safety concerns. In studies with high-risk patients who were not hospitalized, it helped prevent severe cases of COVID-19. These results suggest that PF-07817883 could be a promising treatment for people with COVID-19. Participants in this trial will receive different dosing regimens of PF-07817883 to evaluate its effectiveness and safety.36789
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Single Ascending Dose
Participants receive single ascending doses of PF-07817883 to evaluate safety and pharmacokinetics
Multiple Ascending Dose
Participants receive multiple ascending doses of PF-07817883 to evaluate safety and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PF-07817883
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University